Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Abstract

Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001] This application is a continuation in part of the U.S. patent application Ser. No. ______, filed Nov. 6, 2001, Attorney Docket No. 014058-013520US, entitled COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES, which is a continuation in part of U.S. Ser. No. 09 / 796,692 filed Mar. 1, 2001, which claims priority to United States Provisional Patent Application Serial Nos. 60 / 186,126, filed Mar. 1, 2000; Serial No. 60 / 190,479, filed Mar. 17, 2000; Serial No. 60 / 200,545, filed Apr. 27, 2000; Serial No. 60 / 200,303, filed Apr. 28, 2000; Serial No. 60 / 200,779, filed Apr. 28, 2000; Serial No. 60 / 200,999; filed May 1, 2000; Serial No.60 / 202,084, filed May 4, 2000; Serial No. 60 / 206,201, filed May 22, 2000; Serial No. 60 / 218,950, filed Jul. 14, 2000; Serial No. 60 / 222,903, filed Aug. 3, 2000; Serial No. 60 / 223,416, filed Aug. 4, 2000; and Serial No. 60 / 223,378, filed Aug. 7, 2000; the entire specificatio...

AI Technical Summary

Benefits of technology

0047] It will also be understood that the kits, and compositions of the present invention comprise in an overall and general sense at least one or more particular polynucleotides, polypeptides, and peptides that comprise one or more contiguous sequence regions from one or more of the nucleic acid sequences disclosed herein in SEQ ID NOs:10,486-10,536; SEQ ID NOs:10,537-10,580; SEQ ID NOs:10,581-10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; SEQ ID NO:10,974; SEQ ID NO:10,469, SEQ ID NO:10,470; and SEQ ID NO:10,480 or from one or more of the amino acid sequences encoded by any one of the above polynucleotides or disclosed in any one of SEQ ID NOs:10,471-10,474; SEQ ID NO:10,481; SEQ ID NOs:10,599-10,819; SEQ ID NOs:10,820-10,842; SEQ ID NOs:10,849-10,908; and SEQ ID NOs:10,909-10,968, and that such peptide, polypeptide and polynucleotide compositions may be used in one or more of the particular methods and uses disclosed herein for the diagnosis, detection, prophylaxis, and therapy of one or more hematological cancers, and in particular, lymphomas of a variety of specific types. It will also be understood to the skilled artisan having benefit of the teachings of the present Specification, that the peptide and polypeptide compositions may be used to generate a T cell or an immune response in an animal, and that such compositions may also be administered to an animal from which immunospecific antibodies and antigen binding fragments may be isolated or identified that specifically bind to such peptides or polypeptides. Such an artisan will also recognize that the polynucleotides identified by the present disclosure may be used to produce such peptides, polypeptides, antibodies, and antigen binding fragments, by recombinant protein production methodologies that are also within the capability of the skilled artisan having benefit of the specific ami

Problems solved by technology

Hematological malignancies are generally serious disorders, resulting in a variety of symptoms, including bone marrow failure and organ failure.

Treatment for many hematological malignancies, including leukemias and lymphomas, remains difficult, and existing therapies are not universally effective.

While treatments involving specific immunotherapy appear to have considerable potential, such treatments have been li

Images